http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-9700591-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 1997-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd7528b8b3d287febc48223c1851a3aa |
| publicationDate | 2000-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-9700591-A1 |
| titleOfInvention | Use of naphthalene derivatives for the treatment of lung carcinoma |
| abstract | The present invention relates to the use of compounds of formula (I) in the manufacture of a medicament for inhibiting cell growth in squamous cell lung carcinoma. In the general formula (I), R1 is a 5-7 membered heterocyclic tube having an optionally substituted, saturated or partially unsaturated 1-2N atom at the N-atom, R2 is -R4, -OR-R4, -OS (O) 2-R4, -NR4R5, R4- (CH2) b-NH (C = X) - (CH2) c-, R4- (CH2) bO (C = O) NH- (CH2) c- (C = O) NH-, R4 - (C = O) NH- (C = O) NH-, - (CH2) b-NH (C = X) - (CH2) c-R4, R4- (CH2) bO (C = O) - (CH2 ) c-, - (CH2) bO (C = O) - (CH2) c-R4, -NH (C = X) NH-R4, R4-O (C = O) O-, -O (C = O ) NH-R4, R4-O (C = O) NH-, - (CH2) b- (C = O) - (CH2) c-R4, -NH-S (O) 2-R4, -C (OH ) R4R5, -CH (OH) -R4, - (C = O) -NR4R5, -CN, -NO2, R4- (CR6R7) fO- (CR8R9) g-, alkyl-substituted alkyl, powdered, unsubstituted or unsubstituted alkenyl- or alkenylalkenyl- R3 is a port at any carbon atom of the naphthalene ring capable of forming a further bond, R4 and R5 are each independently a 5-6 membered, optionally substituted and optionally decensated heteroaromatic ring, hydrogen atom, C F3, alkyl or alkylaryl, R6 and R7 are independently hydrogen or alkyl, R8 and R9 are independently hydrogen or, optionally, fluorine-substituted alkyl, 0 and 2, 1 and 2, 3, 4,5 or 6, so b + c is at most 6, f is 0, 1, 2, 3, 4,5 or 6, g is 0, 1, 2 or 3. ŕ |
| priorityDate | 1996-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.